Spondyloarthritis & psoriatic arthritis
Clinical profile and treatment utilisation based on HLA-B*27 status in axial spondyloarthritis: results from ASAS-PerSpA study
Authors' conclusion
HLA-B*27 (-) axSpA patients had a longer delay in diagnosis, more frequently had peripheral arthritis, enthesitis, IBD, psoriasis, and were more often treated with csDMARDs compared to HLA-B*27 (+) subgroup.
Study context
- Population
- Patients fulfilling the 2009 ASAS classification criteria for axSpA and typed for HLA-B*27, 24 countriesof 2910 with axSpA
- Participants
- 2,269 patients
- Comparison
- HLA-B*27 vs HLA-B*27 axSpA
- HLA-B*27(+)n = 1,753reference
- HLA-B*27(-)n = 516
- Primary endpoint
- Clinical features, extra-musculoskeletal manifestations and treatment utilisation by HLA-B*27 status; predictors of HLA-B*27 negativity
Methodological detailsglobal cohort (24 countries), multivariable logistic regression
- Global cohort (24 countries)
- Multivariable logistic regression
Primary result
As reported in the abstract
Predictors of HLA-B*27(-) status, multivariable logistic regression
HLA-B*27(-) vs HLA-B*27(+)Odds ratio (CI)
Enthesitis; positive association
1.27(1.02–1.57)
Psoriasis; positive association
1.84(1.36–2.48)
IBD; positive association
4.84(3.23–7.30)
Uveitis; inverse association
0.37(0.27–0.50)
Further findings
| Outcome | P value |
|---|---|
| Peripheral arthritisHLA-B*27(-) vs HLA-B*27(+) | P < 0.05 |
| PsoriasisHLA-B*27(-) vs HLA-B*27(+) | P < 0.001 |
| EnthesitisHLA-B*27(-) vs HLA-B*27(+) | P < 0.001 |
| IBDHLA-B*27(-) vs HLA-B*27(+) | P < 0.001 |
| csDMARD exposureHLA-B*27(-) vs HLA-B*27(+) | P < 0.05 |
- Male sex: HLA-B*27(+) 72.1 %
- Male sex: HLA-B*27(-) 54.3%
- Positive family history of axSpA: HLA-B*27(+) 29.8 %
- Positive family history of axSpA: HLA-B*27(-) 15.3%
- Age at diagnosis: HLA-B*27(+) 31.6 (SD 10.9) years
- Age at diagnosis: HLA-B*27(-) 37.7 (SD 12.1) years
- Peripheral arthritis: HLA-B*27(-) 47.5 %
- Peripheral arthritis: HLA-B*27(+) 42.1%
- Psoriasis: HLA-B*27(-) 19.4
- Psoriasis: HLA-B*27(+) 10.2
- Enthesitis: HLA-B*27(-) 56.6 %
- Enthesitis: HLA-B*27(+) 49.8%
- IBD: HLA-B*27(-) 12.8
- IBD: HLA-B*27(+) 3.4
- csDMARD exposure: HLA-B*27(-) 61.2 %
- csDMARD exposure: HLA-B*27(+) 55.0%
Original publication
Clinical profile and treatment utilisation based on HLA-B*27 status in axial spondyloarthritis: results from ASAS-PerSpA study. RMD Open. Published 25 July 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →